M. D. Malova

M. D. Malova

Auto-generated profile, based on publicly available information

M. D. Malova

N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
KSK. A. Sergeenko
K. A. Sergeenko
EME. B. Machneva
E. B. Machneva
TAT. Z. Aliev
T. Z. Aliev
NBNatalia Burlaka
Natalia Burlaka
OKO. A. Kapkova
O. A. Kapkova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
Germ cell tumors (GCTs) are a heterogeneous group of tumors that develop from pluripotent germ cells, diagnosed most often in infants, young children, adolescents and young adults, and are characterized by different localization, histological picture, clinical course and prognosis. Despite the fairly high efficiency of modern standard chemotherapy protocols for GCTs, the treatment of their relapses and refractory forms, which make up to 30–40 % of all GCTs and have an extremely unfavorable prognosis, is very difficult. Currently, there is no single strategy for the treatment of relapses and refractory forms of GCTs, however, the world and domestic literature presents data on the successful use of high-dose chemotherapy (HDCT) in such patients followed by autologous hematopoietic stem cell transplantation (auto-HSCT). To develop and optimize protocols for this therapy method, and therefore improve the treatment outcomes for patients with relapses and refractory forms of GCT, it is necessary to analyze a larger number of studies from various transplant centers working in this area. The article presents current literature data on the use of HDCT followed by auto-HSCT in patients with GCT, as well as a clinical case of successful 2 courses of HDCT with auto-HSCT in tandem mode in a child with a refractory form of GCT with subsequent maintenance of complete remission for 2 years.

21 July 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
TAT. Z. Aliev
T. Z. Aliev
KKKirill Kirgizov
Kirill Kirgizov
EME. B. Machneva
E. B. Machneva
IKIrina Kostareva
Irina Kostareva
KSK. A. Sergeenko
K. A. Sergeenko
SVS. R. Varfolomeeva
S. R. Varfolomeeva
High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is a therapeutic option that allows potentiating the antitumor effect in patients with malignant neoplasms (MNs) belonging to the high-risk group. However, despite the effectiveness of this method, the risks of developing infectious and toxic complications in the early and late post-transplantation period are higher than the risks associated with treatment according to standard protocols and can significantly worsen the results of transplantation. We carried out a retrospective analysis of the results of auto-HSCT in a cohort of 156 patients with high-risk solid MNs treated at the L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation in 2020–2023. The study was approved by the Independent Ethics Committee and the Scientific Council of the N.N. Blokhin National Medical Research Center of Oncology. The study included 78 (50%) boys and 78 (50%) girls, the median age of the patients was 8 years 7 months (9 months – 17 years 8 months). Auto-HSCT was performed in 90 (57.7%) patients with neuroblastoma, 25 (16.0%) – with Ewing's sarcoma, 16 (10.3%) – with germ cell tumors, 13 (8.4%) – with nephroblastoma, 7 (4.5%) – with retinoblastoma, 3 (1.9%) – with medulloblastoma, 1 (0.6%) patient with pleuropulmonary blastoma and 1 (0.6%) patient with sialoblastoma. We used the following conditioning regimens: treosulfan + melphalan (n = 116), carboplatin + thiotepa + etoposide (n = 17), melphalan (n = 13), carboplatin + thiotepa + etoposide + cyclophosphamide (n = 10). Depending on the clinical indications and the treatment protocol used, 136 (87.2%) patients underwent one course of HDCT, and 20 (12.8%) patients underwent tandem HDCT. In most patients, the median recovery time for granulocytes and platelets was 11 (8–19) days and 14 (12–21) days, respectively. The most common infectious complications in patients after auto-HSCT were mucositis (89.1%), neutropenic enterocolitis (76.9%), febrile neutropenia (71.2%), less often: catheter-associated bloodstream infection (9%), pneumonia (14.1%), acute respiratory distress syndrome (0.6%). As regards toxic complications, all patients had emetic syndrome, 98 (62.8%) had dermatological toxicity, 9 (5.8%) had hemorrhagic cystitis, 116 (74.3%) had hepatic toxicity, 14 (9%) had neurotoxicity, 102 (65.4%) had moderate nutritional insufficiency. Episodes of hemorrhagic syndrome due to thrombocytopenia were observed in 44.2% of patients. After auto-HSCT, most patients develop chemotherapy-induced (including infectious) complications, which can not only significantly disrupt the patients’ well-being and quality of life, but also, depending on the severity, pose a threat to their life. The correct choice of conditioning regimen, effective collection of hematopoietic stem cells, complex accompanying therapy, timely diagnosis and treatment of complications can significantly improve the results of auto-HSCT in children with high-risk solid MNs.

12 May 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IKIrina Kostareva
Irina Kostareva
KKKirill Kirgizov
Kirill Kirgizov
EME. B. Machneva
E. B. Machneva
TAT. Z. Aliev
T. Z. Aliev
YLYu. V. Lozovan
Yu. V. Lozovan
АЕА. Ю. Елфимова
А. Ю. Елфимова
Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment option for relapsed / refractory (R / R) acute leukemia (AL) and high-risk AL. In this article, we present our own experience of allo-HSCT in children with R / R AL. The study was approved by the Independent Ethics Committee and the Scientific Council of the N. N. Blokhin National Medical Research Center of Oncology. Fifty-one patients with R / R AL were included in the study: 32 patients had acute lymphoblastic leukemia (ALL), 17 patients had acute myeloid leukemia (AML) and 2 patients had biphenotypic leukemia (BL). All patients underwent allo-HSCT from January 2021 to October 2022. The median age was 8.7 years (5 months – 17 years). At the time of allo-HSCT, 26 patients were in the second (and further) remission, the rest were in the first clinical and hematologic remission (high-risk AML and refractory ALL). Twenty-one (41.2 %) patients received allo-HSCT from a haploidentical donor, 19 (37.2 %) patients underwent allo-HSCT from an HLA-matched related donor and 11 (21.6 %) patients – from an HLA-matched unrelated donor. Pre-transplant conditioning in ALL: 27 patients received regimens based on total body irradiation at a dose of 12 Gy, 4 patients received busulfan-based conditioning regimens, and in 1 patient we used treosulfan. In AML and BL, we used conditioning regimens based on treosulfan/thiotepa (n = 10), treosulfan/melphalan (n = 8) or busulfan / melphalan (n = 1). Bone marrow (in 14 patients) and peripheral blood stem cells (in 37 patients) were used as a source of hematopoietic stem cells. In haploidentical allo-HSCTs in order to prevent graft-versus-host disease (GVHD) we performed TCRab/CD19 depletion followed by additional administration of abatacept / tocilizumab / rituximab on day –1 in 15 patients, 6 patients received post-transplant cyclophosphamide. In transplantations from HLA-matched related and unrelated donors, patients received combined immunosuppressive therapy with abatacept and rituximab on day –1, and calcineurin inhibitors were used as basic immunosuppressive therapy. All patients engrafted with a median time to engraftment of 13 (range, 9 to 24) days after allo-HSCT. Eight (15.7 %) patients developed a relapse of AL at different times after HSCT (five of them are alive). At the median follow-up of 9 (5–25) months, the overall and disease-free survival survival rates were 76.4 % and 68.8 %, respectively, for patients with AL. Acute GVHD was observed in 72.5 % of children, grade 3–4 GVHD was observed in 5.3 % of patients, and 13.7 % of children developed chronic GVHD. Most patients developed infectious complications in the early post-transplant period: febrile neutropenia (96.0 %), reactivation of viremia (47.3 %,) oropharyngeal mucositis (78.4 %), acute cystitis (12.3 %). The overall mortality rate was 17.6 %. Late mortality was associated with a relapse of AL.

16 August 2022 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
KSK. A. Sergeenko
K. A. Sergeenko
TAT. Z. Aliev
T. Z. Aliev
IKIrina Kostareva
Irina Kostareva
YLYu. V. Lozovan
Yu. V. Lozovan
MMM. D. Malova
M. D. Malova
KKKirill Kirgizov
Kirill Kirgizov
Despite improved understanding of the biology of the disease and the use of multicomponent chemotherapy, the prognosis for children with relapsed or refractory B-line acute lymphoblastic leukemia (B-ALL) remains poor. Currently, the only definitive treatment for these patients is allogeneic hematopoietic stem cell transplantation (allo-HSCT), which can be performed after achieving immunohematological remission. Conducting highintensity polychemotherapy (PCT) blocks to achieve negative values of minimal residual disease (MRD) is often limited due to high toxicity. The developed monoclonal antibodies targeting cell surface antigens, such as CD19 and CD20, are actively used in children with relapsed/refractory B-ALL as part of “bridge therapy”, which allows achieving MRD-negative status without the use of intensive chemotherapy. However, new strategies are needed to improve the prognosis of these patients. The drug Inotuzumab ozogamicin has demonstrated efficacy in relapses of B-ALL and is actively used to achieve a negative MRD status before the allo-HSCT stage in children. In the presented article, in addition to a brief review of the literature, clinical experience with the use of this drug is demonstrated.

19 August 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
KSKarina A. Sergeenko
Karina A. Sergeenko
САСергеенко Карина Андреевна
Сергеенко Карина Андреевна
TAT. Z. Aliev
T. Z. Aliev
АЗАлиев Т. З.
Алиев Т. З.
EME. B. Machneva
E. B. Machneva
ВРВарфоломеева С. Р.
Варфоломеева С. Р.
Background. Germ cell tumors (GCT) in children represent a group of chemosensitive malignant neoplasms. However, for a small subset of patients with refractory, relapsed, or disseminated GCT, the prognosis remains extremely poor, with overall survival rates potentially not exceeding 45%. High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is considered a treatment strategy with the potential to improve outcomes in this patient population. Objective – to analyze the experience of HDCT with auto-HSCT in children with poor-prognosis GCT, with assessment of the efficacy and safety of this therapeutic approach. Materials and methods. This single-center retrospective study enrolled 20 children (9 boys and 11 girls) with relapsed (n = 9), refractory (n = 3), and disseminated (n = 8) forms of GCT who received HDCT followed by auto-HSCT. The median age is 2 (1–18) years. All patients had a graft of adequate cellularity collected prior to transplantation: the median CD34+ cell dose was 3.6 (range 2.0–8.1) ×106/kg body weight. A tandem HDCT regimen was administered to 14 patients (first course: carboplatin 1200 mg/m2, etoposide 1500 mg/m2, second course: etoposide 1500 mg/m2 and thiotepa 900 mg/m2). Six patients received a single-course HDCT regimen (etoposide 1500 mg/m2 and thiotepa 900 mg/m2). The median follow-up was 27 (range 1–61) months. Results. All patients achieved hematopoietic recovery following auto-HSCT. Febrile neutropenia developed in 11 patients (55.0%) during the early post-transplant period, with a mean duration of fever of 4 (range 0–6) days. Oropharyngeal mucositis and gastrointestinal mucositis were observed in all 20 patients (100.0%), and dermatological toxicity was noted in 16 patients (80.0%). In the majority of cases, the severity of toxic and infectious complications did not exceed grade 2. At a median follow-up of 2.7 years, overall survival was 84.0%, event-free survival was 78.0%, and relapse-free survival was 81.0%. Disease progression after auto-HSCT was documented in 3 patients, 2 of whom remain alive. Two patients died: one due to disease progression, and one due to an infectious episode at the place of residence 6 months after the completion of therapy. Conclusion. HDCT with auto-HSCT in children with poor-prognosis GCT may be considered an effective therapeutic approach with an acceptable toxicity profile.

19 August 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DSDarya S. Smirnova
Darya S. Smirnova
СССмирнова Дарья Сергеевна
Смирнова Дарья Сергеевна
TAT. Z. Aliev
T. Z. Aliev
АЗАлиев Т. З.
Алиев Т. З.
EME. B. Machneva
E. B. Machneva
ВРВарфоломеева С. Р.
Варфоломеева С. Р.
Background. Tandem high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is an intensification strategy for consolidation therapy in children with certain high-risk solid malignant neoplasms (SMN). Despite evidence supporting the efficacy of this approach, its tolerability, technical feasibility, and toxicity profile in the pediatric population remain subjects of ongoing investigation. Objective – to analyze the tolerability, toxicity, and technical feasibility of tandem HDCT with auto-HSCT in children with high-risk SMN, including a comparative assessment against single auto-HSCT. Materials and methods. A retrospective-prospective single-center study was conducted, enrolling 115 pediatric patients (median age 48 (range – 7–215) months) with high-risk SMN who underwent HDCT with auto-HSCT. The study group comprised 20 patients who received tandem HDCT with auto-HSCT: 14 with germ cell tumors, 4 with neuroblastoma, 1 with hepatoblastoma, and 1 with sialoblastoma. The historical control group (n = 95) included 74 patients with neuroblastoma, 16 with Ewing sarcoma, and 5 with germ cell tumors, all of whom received single auto-HSCT. A graft of satisfactory quality was successfully collected from all patients in the study group. All patients received a conditioning regimen according to the underlying disease protocol, performance status, and baseline characteristics. Therapy toxicity, outcomes, and transplant-related mortality (TRM) were evaluated. Results. Hematopoietic recovery was achieved in all patients in the study group after both transplantation stages, the median time to neutrophil engraftment was 10.5 and 11.5 days after auto-HSCT №1 and auto-HSCT №2, respectively. Grade III–IV toxic complications were recorded in 40.0% of patients after auto-HSCT №1 and in 90.0% after auto-HSCT №2 (p = 0.001), which was comparable to the historical control group (81.1%). TRM in the study group was 0%. At the time of last follow-up, 17 (85.0%) patients in the study group were alive, of whom 16 (80.0%) were in remission; in the historical control group, 74 (77.9%) patients were alive, of whom 70 (73.7%) were in remission. Conclusion. Tandem HDCT with auto-HSCT is a technically feasible consolidation strategy in children with high-risk SMN, with an acceptable tolerability and toxicity profile. The absence of TRM and a manageable toxicity profile comparable to single auto-HSCT support the expansion of indications for this approach. Further multicenter studies are needed to evaluate long-term outcomes and optimize patient selection criteria.